BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer
Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of April 19 - 25, 2021.
Alerts this week cover papers from New England, Lancet Oncology, BMC Cancer, The Oncologist, Nature Medicine, and JAMA Oncology.
Dr Morgan also highlights the success of the sacituzumab govitecan trial in patients with pre-treated metastatic triple negative breast cancer.
You can watch Dr Morgan's previous roundup here.
Follow Dr Morgan on twitter: @OncoAlert
Follow ecancer on twitter: @ecancer
BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer
Transforming cancer care in India: The Access Cancer Care Initiative
The added value of integrative medicine
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
GIST tumours and soft tissue sarcomas
Best practice in HRRm testing in patients with metastatic prostate cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Choosing Wisely in pathology
Choosing Wisely in radiology Tanzania